SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the mechanisms of action of FORTEO® (teriparatide [rDNA origin] injection) and zoledronic ...
INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data comparing the effects of FORTEO and zoledronic acid on transiliac crest bone biopsies at six months ...
An Oregon Health & Science University-lead study is examining the effectiveness of the synthesized parathyroid hormone, teriparatide -- sold under the brand name FORTEO -- in improving bone mass and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果